JO3376B1 - خليط متحد مضاد للفيروسات المسببة للاورام - Google Patents

خليط متحد مضاد للفيروسات المسببة للاورام

Info

Publication number
JO3376B1
JO3376B1 JOP/2012/0207A JOP20120207A JO3376B1 JO 3376 B1 JO3376 B1 JO 3376B1 JO P20120207 A JOP20120207 A JO P20120207A JO 3376 B1 JO3376 B1 JO 3376B1
Authority
JO
Jordan
Prior art keywords
retroviral combination
retroviral
combination
darunavir
ritonavir
Prior art date
Application number
JOP/2012/0207A
Other languages
English (en)
Inventor
Lulla Amar
Malhotra Geena
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54289250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3376(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cipla Ltd filed Critical Cipla Ltd
Application granted granted Critical
Publication of JO3376B1 publication Critical patent/JO3376B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/03—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor characterised by the shape of the extruded material at extrusion
    • B29C48/04—Particle-shaped
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/25—Component parts, details or accessories; Auxiliary operations
    • B29C48/78—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling
    • B29C48/80—Thermal treatment of the extrusion moulding material or of preformed parts or layers, e.g. by heating or cooling at the plasticising zone, e.g. by heating cylinders
    • B29C48/83—Heating or cooling the cylinders
    • B29C48/832—Heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Abstract

توجد هناك مركبات صيدلانية من ريتونافير ودارونافير كما توجد هناك طرق لانتاجه.
JOP/2012/0207A 2007-12-24 2012-07-29 خليط متحد مضاد للفيروسات المسببة للاورام JO3376B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2538MU2007 2007-12-24

Publications (1)

Publication Number Publication Date
JO3376B1 true JO3376B1 (ar) 2019-03-13

Family

ID=54289250

Family Applications (2)

Application Number Title Priority Date Filing Date
JO2008578A JO2814B1 (ar) 2007-12-24 2008-12-24 خليط متحد مضاد للفيروسات المسببة للأورام
JOP/2012/0207A JO3376B1 (ar) 2007-12-24 2012-07-29 خليط متحد مضاد للفيروسات المسببة للاورام

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JO2008578A JO2814B1 (ar) 2007-12-24 2008-12-24 خليط متحد مضاد للفيروسات المسببة للأورام

Country Status (20)

Country Link
US (1) US9339470B2 (ar)
EP (2) EP2242482B1 (ar)
JP (2) JP2011507940A (ar)
CN (2) CN101925350B (ar)
AP (2) AP2013007064A0 (ar)
AT (1) ATE555778T1 (ar)
AU (1) AU2008339633A1 (ar)
BR (1) BRPI0819534A2 (ar)
CA (1) CA2710605C (ar)
DK (1) DK2242482T3 (ar)
ES (2) ES2385819T3 (ar)
GT (1) GT200800303A (ar)
HK (1) HK1149905A1 (ar)
JO (2) JO2814B1 (ar)
MX (1) MX2010007083A (ar)
PA (1) PA8809601A1 (ar)
PE (2) PE20140926A1 (ar)
RU (2) RU2531089C2 (ar)
WO (1) WO2009081174A2 (ar)
ZA (1) ZA201004505B (ar)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
CA2784398A1 (en) 2010-01-28 2011-08-04 Mapi Pharma Limited Process for the preparation of darunavir and darunavir intermediates
CA2822639A1 (en) * 2010-12-22 2012-06-28 The Feinstein Institute For Medical Research Methods for treating systemic lupus erythematosus using hiv protease inhibitors
KR101817991B1 (ko) * 2011-07-07 2018-01-12 얀센 사이언시즈 아일랜드 유씨 다루나비어 제제
BR112014000290B1 (pt) * 2011-07-07 2022-05-10 Gilead Sciences, Inc. Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir
JP6314131B2 (ja) * 2012-05-03 2018-04-18 シプラ・リミテッド 抗レトロウイルス組成物
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
EP3038607A2 (en) 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
WO2015155673A1 (en) 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
WO2018029561A1 (en) * 2016-08-08 2018-02-15 Hetero Labs Limited Anti-retroviral compositions
RU2659693C1 (ru) * 2017-06-30 2018-07-03 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция, обладающая активностью против ВИЧ-инфекции
EP3569225A1 (en) 2018-05-18 2019-11-20 Pharmaceutical Oriented Services Ltd Solid dispersion containing ritonavir
CN114146061B (zh) * 2020-09-07 2023-06-30 歌礼生物科技（杭州）有限公司 包含固体分散体的蛋白酶抑制剂增效组合物及其制备方法
RU2760129C1 (ru) * 2020-12-04 2021-11-22 Общество с ограниченной ответственностью "АМЕДАРТ" Твёрдая фармацевтическая композиция для изготовления перорального антиретровирусного терапевтического средства

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141867A (en) 1987-02-02 1992-08-25 E. I. Du Pont De Nemours And Company Nucleotide sequence encoding a human immunodeficiency virus antigen
JP2994031B2 (ja) 1988-12-20 1999-12-27 クラリティ テクノロジーズ インコーポレイテッド Ｈｉｖ−１又はｈｉｖ−２抗体の存在又は量の確定方法、免疫特異的試薬、合成ペプチド、診断用キット、ｈｉｖ−１又はｈｉｖ−２抗体の調製方法、免疫原及び抗体
WO1990007199A1 (en) 1988-12-20 1990-06-28 Mawzones Developments Limited Focussing device for a microwave antenna
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US6248574B1 (en) 1989-12-13 2001-06-19 Avigdor Shaffermann Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
IL102092A (en) 1991-06-11 1996-11-14 Microgenesys Inc Use of recombinant VIH protein wrapped in VIH abduction drug and a pharmaceutical preparation containing the accumulated protein
EP0674513B1 (en) 1992-12-29 1996-09-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
WO1999067254A2 (en) 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
TWI286476B (en) 2001-12-12 2007-09-11 Tibotec Pharm Ltd Combination of cytochrome P450 dependent protease inhibitors
RU2275361C3 (ru) 2002-11-20 2021-10-01 Джапан Тобакко Инк. Соединение 4-оксохинолина и его применение в качестве ингибитора вич интегразы
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
ES2313394T3 (es) * 2004-07-08 2009-03-01 Tibotec Pharmaceuticals Ltd. Combinacion de transcriptasa inversa anti-hiv e inhibidores de proteasa.
JP2008520672A (ja) * 2004-11-16 2008-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チプラナビルとダルナビルの共投与によるｈｉｖ感染症の治療方法
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
SI2051703T1 (sl) 2005-12-14 2011-01-31 Cipla Ltd Farmacevtski sestavki, ki vsebujejo inhibitorje nukleotidne in nukleozidne reverzne transkriptaze (kot tenofovir in lamivudin) v različnih delih dozirne oblike
PA8809601A1 (es) 2007-12-24 2009-07-23 Cipla Ltd Combinación anti-retroviral

Also Published As

Publication number Publication date
AP2013007064A0 (en) 2013-08-31
PA8809601A1 (es) 2009-07-23
ES2385819T3 (es) 2012-08-01
CN101925350A (zh) 2010-12-22
RU2531089C2 (ru) 2014-10-20
GT200800303A (es) 2009-09-18
EP2505193A1 (en) 2012-10-03
EP2242482A2 (en) 2010-10-27
MX2010007083A (es) 2010-10-20
CN103638032A (zh) 2014-03-19
AU2008339633A1 (en) 2009-07-02
CA2710605A1 (en) 2009-07-02
JP2011507940A (ja) 2011-03-10
ATE555778T1 (de) 2012-05-15
DK2242482T3 (da) 2012-08-06
US9339470B2 (en) 2016-05-17
US20110008429A1 (en) 2011-01-13
CA2710605C (en) 2017-05-02
WO2009081174A2 (en) 2009-07-02
EP2242482B1 (en) 2012-05-02
CN101925350B (zh) 2014-04-30
WO2009081174A3 (en) 2009-08-27
ZA201004505B (en) 2013-05-29
ES2674730T3 (es) 2018-07-03
RU2010131006A (ru) 2012-02-10
JP2015007071A (ja) 2015-01-15
JO2814B1 (ar) 2014-09-15
BRPI0819534A2 (pt) 2015-05-26
PE20091530A1 (es) 2009-09-25
AP2010005325A0 (en) 2010-08-31
PE20140926A1 (es) 2014-08-06
RU2675831C2 (ru) 2018-12-25
EP2505193B1 (en) 2018-05-02
RU2014111723A (ru) 2015-10-10
AP2855A (en) 2014-02-28
HK1149905A1 (en) 2011-10-21

Similar Documents

Publication Publication Date Title
JO3376B1 (ar) خليط متحد مضاد للفيروسات المسببة للاورام
IL262205A (en) Protein formulations and methods for their preparation
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
HK1210420A1 (en) Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
IL195491A (en) Pharmaceutical preparations containing tmc278 and processes for their preparation
EP2136634A4 (en) MIMETIC GLUCOCORTICOID SUBSTANCES, PREPARATION METHODS THEREOF, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP2152304A4 (en) THERAPEUTIC COMPOSITIONS IN NANOEMULSION FORM AND METHOD OF APPLICATION THEREFOR
ZA200902803B (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP2490679B8 (en) Methods of making and using compositions comprising flavonoids
EP2429948A4 (en) Aerogel compositions and methods of making and using them
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
IL206978A0 (en) Powdered protein compositions and methods of making same
ZA200900347B (en) Preparation of pharmaceutical compositions
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
ZA201008379B (en) Glucocorticoid mimetics,methods of making them,pharmaceutical compositions,and uses thereof
EP2506835A4 (en) COMPRESSIBLE COATED PHARMACEUTICAL COMPOSITION, TABLETS AND MANUFACTURING METHOD THEREFOR
EP2491116A4 (en) CELL-BASED ANTI-RISK COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
IL207724A0 (en) Cns pharmaceutical compositions and methods of use
IL220513A0 (en) Pharmaceutical composition comprising vitamin d analogue and cosolvent-surfactant mixture
MX2009007764A (es) Formulacion de nevirapina de liberacion prolongada.
EP2051721A4 (en) PREPARATION AND PHARMACEUTICAL USE OF COMPOSITION FROM THE EXTRACT OF EUTERPE OLERACEA (ACAI)
MX2010004734A (es) Nueva combinacion anti-retrovirica.
IL219018A (en) Radzolid Pharmaceuticals and Uses
MX2013005699A (es) Composiciones de interferon-beta estables conservadas.